≡

Multiplex Assay Kit for Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay)

K-Glypican; Glypican Proteoglycan 4; Secreted glypican-4

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 82-96 91
EDTA plasma(n=5) 89-96 92
heparin plasma(n=5) 89-101 93
sodium citrate plasma(n=5) 85-95 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 86-99% 94-102% 91-105% 80-90%
EDTA plasma(n=5) 97-105% 79-90% 86-93% 83-98%
heparin plasma(n=5) 91-99% 87-104% 78-99% 86-101%
sodium citrate plasma(n=5) 83-92% 90-99% 93-105% 85-99%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:GPC4) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
PLoS One. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation Pubmed:Pmc4072672
Aspects of fluid therapy in the critically ill. Experimental and clinical studies on fluid therapy in the inflammatory conditions. 250690_2_G5_Svajunas_S.pdf
Intensive Care Medicine Experimental Elevated plasma glypicans are associated with organ failure in patients with infection Pubmed: 30618011
Crit Care Albumin infusion rate and plasma volume expansion: a randomized clinical trial in postoperative patients after major surgery Pubmed: 31138247
J Endocrinol Invest Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with … Pubmed: 32816247
Heparin Binding Protein and Endothelial Glycocalyx Markers in Severe COVID-19–A Prospective Observational Cohort Study
Sci Rep Glypican-4 in pregnancy and its relation to glucose metabolism, insulin resistance and gestational diabetes mellitus status 34903856
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA998Hu01 Recombinant Glypican 4 (GPC4) Positive Control; Immunogen; SDS-PAGE; WB.
PAA998Hu01 Polyclonal Antibody to Glypican 4 (GPC4) WB; IHC; ICC; IP.
LAA998Hu81 FITC-Linked Polyclonal Antibody to Glypican 4 (GPC4) WB; IHC; ICC; IF.
LAA998Hu71 Biotin-Linked Polyclonal Antibody to Glypican 4 (GPC4) WB; IHC; ICC.
MAA998Hu22 Monoclonal Antibody to Glypican 4 (GPC4) WB; IHC; ICC; IP.
SEA998Hu ELISA Kit for Glypican 4 (GPC4) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA998Hu Multiplex Assay Kit for Glypican 4 (GPC4) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.